3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Motor Activity
4
Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Obesity
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Skin Neoplasms
1
Sarcopenia
1
Renal Insufficiency, Chronic
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Overweight
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Locally Advanced Head and Neck Squamous Cell Carcinoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Inflammation
1
Hematopoietic and Lymphatic System Neoplasm
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
22
Nivolumab
14
enfortumab vedotin
13
Gemcitabine
11
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Cisplatin
8
Carboplatin
8
sacituzumab govitecan
6
avelumab
6
Docetaxel
6
atezolizumab
5
Ipilimumab
5
durvalumab
4
Paclitaxel
4
cabozantinib
3
Taxes
3
Mitomycin
3
CTLA-4 Antigen
3
tislelizumab
2
relatlimab
2
erdafitinib
2
disitamab vedotin
2
Radiosurgery
2
Platinum
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorouracil
2
Disulfides
2
ALT-803
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Resistance Training
×
90 days
×
Clear all
No trials found.